Background/Objectives: This nationwide population-based study investigated the overall survival (OS) of patients with metastatic pancreatic cancer (mPC) receiving first-line chemotherapy. Methods: Data from the National Health Insurance Service linked to the Korea Central Cancer Registry were used. Patients with mPC receiving first-line chemotherapy (2012–2019) were included and followed up until 2020. The gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX groups were matched according to age, sex, and comorbidities. Results: In total, 8652 patients with mPC were treated with chemotherapy. GnP and FOLFIRINOX have been administered since 2016 and 2017, respectively. The median OS increased annually from 6 months in 2012–2013 to 10 months in 2018–2019. The median OSs in the GnP and FOLFIRINOX groups were significantly longer than those in patients receiving gemcitabine ± erlotinib. A total of 1134 patients from both the GnP and FOLFIRINOX groups were selected using propensity score matching. Before matching, the median OS was longer in the FOLFIRINOX group than in the GnP group (p= 0.0029). After matching, however, there was no significant difference in the median OS between the two groups (11 vs. 11 months, respectively,p= 0.2438). Conclusions: Patients with mPC receiving chemotherapy have shown improved OS since the introduction of GnP and FOLFIRINOX. After matching, OS did not differ between the GnP and FOLFIRINOX groups.
背景/目的：这项全国性人群队列研究旨在探讨接受一线化疗的转移性胰腺癌（mPC）患者的总生存期（OS）。方法：研究数据来源于韩国国民健康保险服务数据库与中央癌症登记处的关联信息。纳入2012年至2019年间接受一线化疗的mPC患者，随访至2020年。对吉西他滨联合白蛋白结合型紫杉醇（GnP）方案组与FOLFIRINOX方案组患者进行年龄、性别及合并症的匹配分析。结果：共有8652例mPC患者接受化疗。GnP方案与FOLFIRINOX方案分别自2016年与2017年开始应用。中位OS从2012-2013年度的6个月逐年提升至2018-2019年度的10个月。GnP组与FOLFIRINOX组的中位OS均显著长于接受吉西他滨±厄洛替尼治疗的患者。通过倾向评分匹配从两组中分别选取1134例患者进行分析。匹配前，FOLFIRINOX组中位OS长于GnP组（p=0.0029）；匹配后两组中位OS无显著差异（均为11个月，p=0.2438）。结论：自GnP与FOLFIRINOX方案应用以来，接受化疗的mPC患者OS呈现改善趋势。经匹配分析后，GnP组与FOLFIRINOX组患者的OS未见显著差异。
肿瘤(癌症)患者之家